Par Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Malvern PA United States (1978)
Status: Acquired by Endo Pharmaceuticals (2015) → now Bristol-Myers Squibb (2001)

Organization Overview

First Clinical Trial
1998
NCT00653419
First Marketed Drug
1978
estradiol (progynon depot)
First NDA Approval
1979
nalbuphine (nubain)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PAR FORM | PAR FORMULATIONS PRIVATE LTD | PAR PHARM | Par Pharmaceutical Companies, Inc. | Par Pharmaceutical, Inc. | PAR PHARM INC | PAR STERILE PRODUCTS